MGMT and pituitary adenocarcinoma: In addition, MGMT promoter methylation tended to be more common in the aggressive pituitary adenomas, with 33 % in pituitary carcinomas, 42 % in SS3 adenomas, and 43 % in aggressive pituitary adenoma [12, 38].